Royalty Pharma plc Net Income Loss

• Royalty Pharma plc showed a decrease of -10.2% in Net Income Loss from 2024 to 2025.
• This data is from Royalty Pharma plc's annual report (Form 10-K), filed with the SEC on February 11, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Royalty Pharma plc's Net Income Loss has declined by 44.0%.
• Historical annual values: Fiscal year 2025: $770.95 million | Fiscal year 2024: $858.98 million | Fiscal year 2023: $1.13 billion | Fiscal year 2022: $42.83 million | Fiscal year 2021: $619.73 million | Fiscal year 2020: $975.04 million | Fiscal year 2019: $2.35 billion | Fiscal year 2018: $1.38 billion.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026